Ginkgo Bioworks is expanding its ability to help other companies make cell and gene therapies, this time by acquiring a startup with tools to improve cell-based treatments.
Ginkgo on Tuesday announced it has bought Modulus Therapeutics, a Seattle-based biotechnology startup. Ginkgo didn’t disclose the financial terms, but noted in a statement that the technology Modulus owns has the potential to boost the safety and efficacy of cell therapies.
